October 24, 2018
Archive

Senate blocks efforts to allow Rx drug imports

WASHINGTON – In a triumph for the pharmaceutical industry, the Senate on Monday killed a drive to allow consumers to buy prescription drugs from abroad at a significant savings over domestic prices.

On a 49-40 vote, the Senate required the administration to certify the safety and effectiveness of imported drugs before they can be imported, a requirement that officials have said they cannot meet.

Maine’s Republican Sens. Olympia Snowe and Susan Collins voted against the amendment.

Snowe in a press release expressed disappointment that progress in advancing access to affordable prescription drug prices “was blocked by a certification requirement.”

“Twice before we have seen the Congress adopt a requirement for the secretary [of Health and Human Services] to certify safety and savings before implementing a program of prescription drug importation,” she said. “And since that time, not a single prescription drug has been imported under the MEDS [Medicine Equity and Drug Safety] Act of 2000 or the Medicare Modernization Act of 2003.”

Maine AARP Director Jud Dolphin, commending Snowe and Collins for their votes, said the amendment was “simply another attempt to keep importation from becoming a reality.”

Sen. David Vitter, a Louisiana Republican, said, “Well, once again the big drug companies have proved that they are the most powerful and best-financed lobby in Washington.”

The vote neutralized a second amendment, later passed on a voice vote that would legalize importation of prescription drugs manufactured in Canada, Australia, Europe, Japan and New Zealand.

Sen. Bernie Sanders, a Vermont independent, called the certification amendment, introduced by Sen. Thad Cochran, R-Miss., a “poison pill” for the drug-imports legislation. Sen. Byron Dorgan, D-N.D., acknowledged it nullified his bid to allow the purchase of drugs abroad.

“This is a setback for us. But the drug industry is one of the strongest industries in this town,” Dorgan said.

Sen. Mike Enzi, a Wyoming Republican, said the requirement for a safety certification was essential to protect the public.

“Under both Democratic and Republican administrations, secretaries of Health and Human Services have declined to certify that foreign drugs – like those allowed under the Dorgan Foreign Drug Act – are safe for American consumers. They realized, as I do, that close enough isn’t good enough,” Enzi said.

The maneuvering occurred on broader legislation to renew the FDA’s ability to collect fees from the drug industry to defray the cost of reviewing new drugs. Lawmakers have seized on the bill to overhaul the agency, including its handling of drug-safety issues highlighted in the wake of the withdrawal of the painkiller Vioxx.

Advocates of drug importation have argued for years that an existing ban is more a protection for the drug industry than a safety issue.

Overseas, drugs can cost two-thirds less than they do in the United States, where prices for brand-name drugs are among the highest in the world. In many industrialized countries, prices are lower because they are either controlled or partially controlled by government regulation.

Dorgan said allowing imports would drive down the price of U.S. brand-name drugs. He said 90 doses of the cholesterol drug Lipitor costs $321 in the U.S. – about twice the cost in Canada.

The idea of allowing prescription drug imports enjoys broad popular support. However, lower prices overseas would not automatically translate into large savings for domestic consumers, according to a 2004 study by the Congressional Budget Office.

The study found that allowing drug imports from a broad set of countries would cut U.S. drug spending by $40 billion over 10 years, about a 1 percent savings. It said foreign governments could limit drug exports to protect their own domestic supplies, and that U.S. drug companies could respond to an importation bill by increasing prices abroad.

The pharmaceutical industry vehemently opposes allowing drug imports, arguing that they could leave the nation vulnerable to dangerous counterfeits.

Similar drug-import legislation is pending in the House.


Have feedback? Want to know more? Send us ideas for follow-up stories.

comments for this post are closed

You may also like